Abstract:Background and objective: Peak width of skeletonized mean diffusivity (PSMD), a fully automated diffusion tensor imaging (DTI) biomarker of white matter (WM) microstructure damage, has been shown to be associated with cognition in various WM pathologies. However, its application in schizophrenic disease remains unexplored. This study aims to investigate PSMD along with other DTI markers in first-episode schizophrenia patients compared to healthy controls (HCs), and explore the correlations between these metrics and clinical characteristics. Methods: A total of 56 first-episode drug-naive schizophrenia patients and 64 HCs were recruited for this study. Participants underwent structural imaging and DTI, followed by comprehensive clinical assessments, including the Positive and Negative Syndrome Scale (PANSS) for patients and cognitive function tests for all participants. We calculated PSMD, peak width of skeletonized fractional anisotropy (PSFA), axial diffusivity (PSAD), radial diffusivity (PSRD) values, skeletonized average mean diffusivity (MD), average fractional anisotropy (FA), average axial diffusivity (AD), and average radial diffusivity (RD) values as well as structural network global topological parameters, and examined between-group differences in these WM metrics. Furthermore, we investigated associations between abnormal metrics and clinical characteristics. Results: Compared to HCs, patients exhibited significantly increased PSMD values (t = 2.467, p = 0.015), decreased global efficiency (Z = -2.188, p = 0.029), and increased normalized characteristic path length (lambda) (t = 2.270, p = 0.025). No significant differences were observed between the groups in the remaining metrics, including PSFA, PSAD, PSRD, average MD, FA, AD, RD, local efficiency, normalized cluster coefficient, small-worldness, assortativity, modularity, or hierarchy (p > 0.05). After adjusting for relevant variables, both PSMD and lambda values exhibited a significant negative correlation with reasoning and problem-solving scores (PSMD: r = -0.409, p = 0.038; lambda: r = -0.520, p = 0.006). No statistically significant correlations were observed between each PANSS score and the aforementioned metrics in the patient group (p > 0.05). Multivariate linear regression analysis revealed that increased PSMD (β = -0.426, t = -2.260, p = 0.034) and increased lambda (β = -0.490, t = -2.994, p = 0.007) were independently associated with decreased reasoning and problem-solving scores respectively ( R a d j 2 = 0.295, F = 2.951, p = 0.029). But these significant correlations did not withstand FDR correction (p_FDR > 0.05). Conclusion: PSMD can be considered as a valuable neuroimaging biomarker that complements conventional diffusion measurements for investigating abnormalities in WM microstructural integrity and cognitive functions in schizophrenia.

DNA Methylation Basis in the Effect of White Matter Integrity Deficits on Cognitive Impairments and Psychopathological Symptoms in Drug-Naive First-Episode Schizophrenia.

DNA Methylation in Schizophrenia: Progress and Challenges

565 – Abnormality of White Matter Structure and Resting State Brain Function in First-Episode, Treatment-Naive Patients with Major Depressive Disorder

Reduced White Matter Integrity Associated with Cognitive Deficits in Patients with Drug-Naive First-Episode Schizophrenia Revealed by Diffusion Tensor Imaging.

Two Patterns of White Matter Abnormalities in Medication-Naive Patients With First-Episode Schizophrenia Revealed by Diffusion Tensor Imaging and Cluster Analysis.

Reduced White Matter Integrity and Cognitive Deficit in Never-Medicated Chronic Schizophrenia: A Diffusion Tensor Study Using TBSS

Genome-wide DNA methylation analysis of peripheral blood cells derived from patients with first-episode schizophrenia in the Chinese Han population

Fronto-parietal white matter microstructural deficits are linked to performance IQ in a first-episode schizophrenia Han Chinese sample.

The role of the white matter integrity of the anterior commissure in cognitive functions in first-episode schizophrenia

White matter microstructure in first-episode schizophrenia:diffusion tensor imaging study using tract-based spatial statistics analysis

White matter alterations in first episode treatment-naïve patients with deficit schizophrenia: a combined VBM and DTI study

Abnormal White Matter Microstructure in Drug-Naive First Episode Schizophrenia Patients Before and after Eight Weeks of Antipsychotic Treatment.

Association between reduced white matter integrity in the corpus callosum and serotonin transporter gene DNA methylation in medication-naive patients with major depressive disorder

Peak width of skeletonized mean diffusivity as a neuroimaging biomarker in first-episode schizophrenia

Methylation Patterns in Whole Blood Correlate with Symptoms in Schizophrenia Patients.

Integrative omics analysis reveals epigenomic and transcriptomic signatures underlying brain structural deficits in major depressive disorder

Structural white matter abnormalities in Schizophrenia and associations with neurocognitive performance and symptom severity

White-matter microstructure in previously drug-naive patients with schizophrenia after 6 weeks of treatment.

The association of DNA methylation and brain volume in healthy individuals and schizophrenia patients

Cognitive Deficits and White Matter Abnormalities in Never-Treated First-Episode Schizophrenia.

DNA Methylation Differences in Cortical Grey and White Matter in Schizophrenia.